SCHEMBL19377373

SCHEMBL19377373

C[C@H](NC(=O)Nc1ccc(S(=O)(=O)Cc2ccc(C(=O)O)cc2)cc1)c1cccc(Cl)c1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ NAMPT P43490 2/20 0.41
▸ CA12 O43570 3/20 0.40
▸ CA2 P00918 3/20 0.40
▸ CA9 Q16790 3/20 0.40
▸ CA1 P00915 2/20 0.40
▸ ITGB1 P05556 2/20 0.40
▸ ITGA4 P13612 2/20 0.40
▸ PPARG P37231 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ IDH1 O75874 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ RORC P51449 1/20 0.38
▸ FAAH O00519 1/20 0.38
▸ MGLL Q99685 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ LMNA P02545 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19377177 0.91 POLB (0.43) NAMPTCA12CA2CA9CA1
SCHEMBL19377419 0.91 KLKB1 (0.41) NAMPTCA12CA2CA9CA1
SCHEMBL19377420 0.91 KLKB1 (0.41) NAMPTCA12CA2CA9CA1
SCHEMBL19377574 0.91 HIF1A (0.41) TSHRHSD17B10NAMPTCA12CA2
SCHEMBL19398857 0.91 MAPT (0.45) NAMPTALDH1A1KMT2ASMN1; SMN2CYP2C9
SCHEMBL19377517 0.90 KMT2A (0.41) NAMPTITGB1ITGA4KMT2AIDH1
SCHEMBL19377399 0.90 SCN3A (0.44) NAMPTCA12CA2CA9CA1
SCHEMBL19377454 0.90 NAMPT (0.40) NAMPTCA12CA2CA9CA1
SCHEMBL19377456 0.90 NAMPT (0.40) NAMPTCA12CA2CA9CA1
SCHEMBL19377515 0.90 KMT2A (0.41) NAMPTITGB1ITGA4KMT2AIDH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170275301-A1 Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof HELSINN HEALTHCARE SA (CH) 2017-09-28 — — US claimed
US-20170275301-A1 Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof HELSINN HEALTHCARE SA (CH) 2017-09-28 — — US disclosed
US-20170275301-A1 Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof HELSINN HEALTHCARE SA (CH) 2017-09-28 — — US disclosed
US-20170275301-A1 Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof HELSINN HEALTHCARE SA (CH) 2017-09-28 — — US disclosed
WO-2017162390-A1 BENZENESULFONYL-ASYMMETRIC UREAS AND MEDICAL USES THEREOF HELSINN HEALTHCARE SA (CH) 2017-09-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170275301-A1 Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof UTS2R, GHSR, GRPR TSHR 93/4885HSD17B10 2852/4885NAMPT 3742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback